Lawrence Cher
Overview
Explore the profile of Lawrence Cher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gan H, Parakh S, Osellame L, Cher L, Uccellini A, Hafeez U, et al.
Expert Opin Biol Ther
. 2023 Nov;
23(11):1089-1102.
PMID: 37955063
Introduction: Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience...
2.
Gunjur A, Balasubramanian A, Hafeez U, Menon S, Cher L, Parakh S, et al.
J Neurooncol
. 2022 Aug;
159(3):551.
PMID: 35994157
No abstract available.
3.
Gunjur A, Balasubramanian A, Hafeez U, Menon S, Cher L, Parakh S, et al.
J Neurooncol
. 2022 Aug;
159(3):539-549.
PMID: 35933567
Purpose: Limited progress has been made in treating glioblastoma, and we hypothesise that poor concordance between preclinical and clinical efficacy in this disease is a major barrier to drug development....
4.
Parakh S, Davies A, Westcott K, Roos D, Abou-Hamden A, Ahern E, et al.
J Clin Neurosci
. 2022 Jun;
102:65-70.
PMID: 35728397
Medulloblastoma in adult patients is a rare condition with limited contemporary demographic and treatment outcome data available in an Australian population. We conducted a retrospective review of patterns of care...
5.
Senko C, Gunjur A, Balasubramanian A, Gan H, Parakh S, Cher L
Asia Pac J Clin Oncol
. 2022 Mar;
18(6):515-525.
PMID: 35238161
The advent of systemic therapies with high intracranial efficacy in recent years is changing the therapeutic paradigm and renewing interest in the management of central nervous system (CNS) and leptomeningeal...
6.
Wong J, Cher L, Griffiths J, Cohen A, Huang J, Wang L, et al.
Hemasphere
. 2019 Nov;
2(6):e155.
PMID: 31723793
No abstract available.
7.
Hovey E, Field K, Rosenthal M, Barnes E, Cher L, Nowak A, et al.
Neurooncol Pract
. 2019 Aug;
4(3):171-181.
PMID: 31386014
Background: In patients with recurrent glioblastoma, the benefit of bevacizumab beyond progression remains uncertain. We prospectively evaluated continuing or ceasing bevacizumab in patients who progressed while on bevacizumab. Methods: CABARET,...
8.
Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment
Hafeez U, Menon S, Nguyen B, Lum C, Gaughran G, Pranavan G, et al.
J Clin Neurosci
. 2019 Aug;
68:45-50.
PMID: 31371189
There is limited information on the patterns of care and outcomes of high grade gliomas (HGGs) in young adults, in particular, the impact it has on a person's employment. We...
9.
Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, et al.
J Clin Neurosci
. 2018 Oct;
56:127-130.
PMID: 30318071
Multi-disciplinary team meetings (MDTs) are considered essential to quality cancer care. For some malignancies, MDTs have been associated with improved outcomes, but data regarding the neuro-oncology MDT is limited. We...
10.
Arulananda S, Lynam J, Liew M, Wada M, Cher L, Gan H
Intern Med J
. 2018 Jun;
48(10):1206-1214.
PMID: 29923272
Background/aim: This study was conducted retrospectively to evaluate rates of thrombocytopenia and their clinical impact during chemo-radiotherapy for glioblastomas and to elucidate associated clinical factors. Methods: A total of 64...